British-based GW Pharmaceuticals announced positive Phase 3 study results of its drug Epidiolex for two treatment-resistant forms of epilepsy, at the 70th Annual Meeting of the American Epilepsy Society in Houston. Epidiolex is an oral formulation of cannabidiol (or CBD), one of 500 compounds found in cannabis.  Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does […]

by

The NSW government has funded the world’s largest trial of medicinal cannabis that will prevent the side effects of chemotherapy. Patients who undergo chemotherapy treatment experience nausea, vomiting and for some, bouts of oesaphigitis or inflammation of the oesephagus. Chris O’Brien Lifehouse’s associate professor Peter Grimison will lead the trial. It will be in collaboration […]

by

– Three Positive Phase 3 Epidiolex clinical trials reported in 2016 –– NDA submission and launch preparation on track –– Conference call today at 8:00 a.m. EST – LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel […]

by

DEVON, Pa., Nov. 28, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its patent-protected synthetic CBD gel,  have been selected for presentation at the upcoming 70th Annual Meeting of the American Epilepsy […]

by